Biotech Stocks Surge as Clinical Updates Ignite Investor Interest
By ATTN Desk · Editorial oversight: Sean Han
Daily Market Recap – July 31, 2025
The final trading session of July saw a broad rally across small-cap and biotechnology stocks, driven largely by clinical trial updates and renewed investor interest in late-stage pipeline candidates. Notable momentum in several names propelled overall volume higher than average, underscoring the market’s appetite for high-growth, event-driven equities.
Key Quotes of the Day
“Today’s action highlights how biotech catalysts can rapidly reshape market sentiment, especially among under-the-radar microcaps.”
— Market Strategist (unbiased observation)
Intraday Price Summary
| Ticker | ATTN Price | Current Price | Volume | Price Change % |
|---|---|---|---|---|
| ONCO | 2.53 | 3.50 | 8,740,347 | 38.25% |
| IXHL | 0.31 | 0.49 | 175,948,378 | 58.15% |
| ALGN | 110.24 | 129.25 | 9,061,336 | 17.27% |
| HCTI | 0.02 | 0.03 | 271,472,501 | 35.76% |
| VRME | 0.95 | 1.51 | 92,838,169 | 58.65% |
| SNGX | 0.92 | 2.99 | 211,008,906 | 224.10% |
| PBM | 2.36 | 4.85 | 18,006,573 | 105.18% |
| RAYA | 0.02 | 0.06 | 198,651,572 | 221.82% |
| RBLX | 123.42 | 137.03 | 13,991,963 | 11.01% |
| APLD | 11.28 | 13.00 | 91,203,386 | 15.25% |
| GRI | 1.06 | 1.29 | 1,079,549 | 22.21% |
| LUNG | 1.59 | 1.85 | 3,272,753 | 16.00% |
| FIEE | 1.89 | 2.75 | 571,821 | 45.75% |
| XBP | 0.94 | 1.29 | 4,169,336 | 37.84% |
| PI | 133.67 | 154.75 | 1,901,464 | 15.74% |
| LXEH | 1.39 | 2.01 | 3,059,279 | 45.16% |
| BINI | 0.04 | 0.04 | 107,479,003 | 18.66% |
| SLXN | 7.07 | 14.01 | 1,319,861 | 98.23% |
| OTRK | 0.16 | 0.30 | 3,784,484 | 95.76% |
| NEGG | 37.88 | 58.21 | 1,901,890 | 53.73% |
Biotech Rally by CDC
Market Trends and Patterns
Biotechnology and small-cap names dominated today’s leaderboard, with over a dozen tickers posting double-digit advances. Several patterns emerged:
-
Event-Driven Moves
Companies with pending clinical readouts or regulatory submissions saw outsized gains. SNGX (+224.10%) led the charge after sharing top-line data from its SGX945 orphan disease study, while RAYA (+221.82%) followed suit on news of a $3 million funding round for expansion. -
Volume Surges
Trading volume spiked for high-flyers, indicating strong liquidity and broad participation:- IXHL (175 million shares)
- SNGX (211 million shares)
- RAYA (198 million shares)
-
Biotech vs. Tech
While names like RBLX (+11.01%) and ALGN (+17.27%) posted solid gains, the biotech cohort—particularly micro-caps under $5—outperformed, reflecting a risk-on stance among speculative traders.
Highlighted Movers
• Soligenix, Inc. (SNGX)
Surged 224.10% to $2.99 on record volume after unveiling positive SGX945 Phase 2 data, setting the stage for potential FDA Priority Review.
• Erayak Power Solution Group (RAYA)
Climbed 221.82% to $0.063 on a $3 million share offering aimed at scaling automation and product development in energy storage.
• Psyence Biomedical Ltd (PBM)
Jumped 105.18% to $4.85 as the company announced the launch of its Phase IIb trials and the addition of key advisors to its board.
• Silexion Therapeutics (SLXN)
Nearly doubled (+98.23%) after reporting encouraging preclinical results for its KRAS-targeting RNAi therapy, despite pending Nasdaq equity requirements.
• Ontrak Inc. (OTRK)
Rebounded 95.76% on renewed optimism following management’s disclosure of robust inpatient engagement metrics, reversing recent executive-change headwinds.
TL;DR
- Biotech micro-caps led a broad rally, with five names more than doubling.
- SNGX and RAYA paced the market, each surging over 220% on clinical and funding announcements.
- Volume topped 200 million shares in two tickers, highlighting elevated trading activity.
- Small-cap momentum outshone larger tech and consumer names, reflecting a risk-on tilt.